Cannabis Law Report

JANUARY 14, 2020

601 , the “Medical Cannabis Research Act of 2019” H.R. 3797 , the “Medical Marijuana Research Act of 2019” H.R. 3884 , the “Marijuana Opportunity Reinvestment and Expungement Act of 2019” or the “MORE Act of 2019” Witnesses. Drug Enforcement Administration.

Clinical Trials

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. On March 5, 2019, the U.S. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*.

Clinical Trials

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,

Clinical Trials

Cannabis Law Report

MARCH 2, 2020

In March 2019, J&J’s hard work paid off when the FDA approved Spravato for treatment-resistant depression. Any approved medicines will have to be rescheduled by the Drug Enforcement Administration (DEA). Fortunately, this issue shouldn’t be a show-stopper. Potential IPOs within the next year.

Medicine

Cannabis Law Report

DECEMBER 21, 2021

It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. Within a few months, it had completed the first phase of its clinical trial of DMT in combination with supportive psychotherapy and commenced a phase 2a trial. Small Pharma (CVE: DMT ) (OTCMKTS: DMTTF ).

Clinical Trials

SpeedWeed

MARCH 5, 2021

One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research.

Business

Cannabis Law Report

JANUARY 11, 2019

Accordingly, the Drug Enforcement Administration (DEA) no longer has any claim to interfere with the interstate commerce of hemp products, so as long as the THC level is at or below 0.3%. While the DEA is now officially out of the hemp regulation business, the U.S. The FDA’s position on CBD is unsettled and unsupported by law.

Hemp

SpeedWeed

DECEMBER 28, 2018

Perhaps my new year’s resolution for 2019 will be more rolling, less scrolling! Or a s like recently retired Speaker of the House John Boehner think that after decades of pushing prohibition they deserved to get rich off cannabis (oh, hell no!). It’s honestly hard to know what to think these days.

Pharmaceutical

Canna Law Blog

MAY 7, 2020

Ole Miss got the cannabis study and research cultivation gig from the DEA (via a contract with the National Institute on Drug Abuse (NIDA)) in 1968. As of December 2019, there are only two patients on the coveted list and no new entrants are permitted. for various studies, including FDA-approved clinical trials.

DEA

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA

Cannabis Law Report

MAY 29, 2022

In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance.

Research and Development

Cannabis Law Report

JUNE 4, 2021

However, Delta 8-THC is explicitly listed on the DEA 7370 Controlled Substance list, so it’s hard to imagine the cases ending in any other way than saying Delta 8-THC should be regulated like cannabis. . . Are there states that you think they’ll let Delta 8 run and be sold alongside other rec products?

Research and Development

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 12, 2019), [link] [ [link] ]. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al.,

Research and Development

Canna Law Blog

NOVEMBER 6, 2021

To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. For two decades, U.S.

Clinical Trials